Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,965,91-4,46
Msft0,23
Nokia3,1683,197-0,03
IBM1,38
Mercedes-Benz Group AG74,474,42-2,14
PFE-0,85
17.04.2024 1:38:42
Indexy online
AD Index online
select
AD Index online
 

  • 16.04.2024 22:00:00
Corcept Thera (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
23,39 1,04 0,24 710 621
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.04.2024
Popis společnosti
Obecné informace
Název společnostiCorcept Therapeutics Incorporated
TickerCORT
Kmenové akcie:Ordinary Shares
RICCORT.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 352
Akcie v oběhu k 06.02.2024 103 517 388
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice149 Commonwealth Dr
MěstoMENLO PARK
PSČ94025
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 506 888 803
Fax16503273218

Business Summary: Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Corcept Therapeutics Incorporated revenues increased 20% to $482.4M. Net income increased 5% to $106.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balancing val increase of 43% to $169M (expense), Other Selling.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 17.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Co-Founder, DirectorJoseph Belanoff6501.01.201401.01.1999
Chief Financial Officer, TreasurerAtabak Mokari4601.03.202101.03.2021
President - Corcept EndocrinologySean Maduck46
President, Emerging MarketsMonica Tellado-01.11.202301.11.2023
President - OncologyRoberto Vieira-29.01.202429.01.2024
Chief Accounting OfficerJoseph Lyon4513.07.202001.01.2012
Chief Scientific OfficerHazel Hunt6301.07.202001.07.2020
Chief Development OfficerWilliam Guyer5516.08.202116.08.2021
Chief Business Officer, SecretaryGary Robb6001.03.202101.09.2011